Ellume gets $232M contract for at-home Covid-19 tests Ellume, whose at-home Covid-19 test was cleared by the FDA in December, got a $232 million contract from the Department of Health and Human Services to deliver 8.5 million tests. Shares1 Ellume’s at-home antigen test does not require a prescription. Users receive their results in a smartphone app. Photo credit: Ellume Diagnostics startup Ellume won a $231.8 million contract from the Department of Health and Human Services to manufacture more of its at-home Covid-19 tests in the U.S. The Brisbane, Australia-based company will open its first U.S. manufacturing facility, with plans to deliver 8.5 million tests as part of its contract.